Reuters logo
Otonomy's ear infection drug succeeds in late-stage trial
January 5, 2017 / 12:23 PM / a year ago

Otonomy's ear infection drug succeeds in late-stage trial

(Reuters) - Drug developer Otonomy Inc said on Thursday its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.

AOE, also known as swimmer’s ear, is a type of bacterial infection causing inflammation in the external ear canal.

The drug, Otiprio, is approved for use in pediatric patients during tympanostomy tube placement surgery.

Children suffering from middle-ear infection, also known as otitis media with effusion (OME), undergo a tympanostomy tube placement surgery to drain out accumulated fluid and simplify the administration of antibiotics.

The company said it would submit a supplemental marketing application with the U.S. Food and Drug Administration in the first half of 2017.

Otiprio, which was approved in late 2015, generated sales of $300,000 in the third quarter of 2016.

There are nearly 4 million cases of AOE each year in the United States, according to the company.

Reporting by Divya Grover in Bengaluru; Editing by Shounak Dasgupta

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below